Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ELI LILLY & Co Director's Dealing 2022

Feb 3, 2022

29745_dirs_2022-02-03_3cec8835-8c36-4326-b8a9-56511125b737.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ELI LILLY & Co (LLY)
CIK: 0000059478
Period of Report: 2022-02-01

Reporting Person: White Anne E. (SVP & Pres-Lilly Neuroscience)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-02-01 Common Stock M 9368 Acquired 43208 Direct
2022-02-01 Common Stock F 4204 $245.39 Disposed 39004 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-02-01 Restricted Stock Unit $ M 9368 Disposed 2022-02-01 Common Stock (9368.0) Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.